Activity of antioxidant enzymes in children from families at high risk of premature coronary heart disease

REFERENCES

• Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Cirulation 1999; 100: 1481— 92.
   Google Scholar
• Pyifordla K, de Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121–61.
   Google Scholar
• Grundy SM. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol 2001; 88: 23J–7J.
   Google Scholar
• Sholtz RI, Rosenman RH, Brand RJ. The relationship of reported parental history to the incidence of coronary heart disease in the Western Collaborative Group Study. Am J Epidemiol 1975; 102: 350–6.
   Google Scholar
• Friedlander Y, Kark JD, Stein Y. Family history of myocardial infarction as an independent risk factor for coronary heart disease. Br Heart J 1985; 53: 382–7.
   Google Scholar
• Assmann G, Schulte H. Identification of indivi-duals at high risk for myocardial infarction. Atherosclerosis 1994; 110: S11–21.
   Google Scholar
• Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation 1980; 61: 503–9.
   Google Scholar
• Raiwater DL, McMaham AC, Malcolm GT, Scheer WD, Roheim PS, McGill HC, Strong JP. Lipid and apolipoprotein predictors of athero-sclerosis in youth. Atherioscler Thromb Vasc Biol 1999; 19: 753–61.
   Google Scholar
• Shah PK. Circulating markers of inflammation for vascular risk prediction. Are they ready for prime time? Circulation 2000; 101: 1758.
   Google Scholar
• Libby P, Ridker P. Novel inflammatory markers of coronary risk. Theory versus practice. Circula-tion 1999; 100: 1148–50.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Primary prevention of coronary heart disease. Integrating risk assessment with intervention. Circulation 1999; 100: 988–98.
   Google Scholar
• Kuller LH. Clinical trials: surrogate endpoints or hard endpoints? Am J Cardiol 2001; 88: 59E–61E.
   Google Scholar
• Ballantyne CM. Surrogate endpoints and newer risk markers in atherosclerosis management. Am J Manag Care 2001; 7: S144–7.
   Google Scholar
• Gmifiski J, Dr62d2 M, Ulfig-Maglanka R, Najda J. Evaluation of elastin metabolsim in children from families with high risk of atherosclerosis. Athero-sclerosis 1991; 91: 185–9.
   Google Scholar
• Wojakowski W, Gmifiski J. Serum levels of soluble ICAM-1, VCAM-1 and E-elastin in children from families with high risk of athero-sclerosis. Int J Mol Med 2001; 7: 181–5.
   Google Scholar
• Wojakowski W, Gmifiski J. Plasma level of von Willebrand factor, endothelin-1, prostacyclin and thromboxane in children from families with high risk of premature coronary artery disease. Scand J Clin Lab Invest 2001; 61: 317–24.
   Web of Science ®Google Scholar
• Mashima R, Witting PK, Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 2001; 12: 411–8.
   Google Scholar
• Chisolm GM, Steinberg D. The oxidative mod-ification hypothesis of atherosclerosis: an over-view. Free Radic Biol Med 2000; 28: 1815–26.
   PubMed Web of Science ®Google Scholar
• Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121–6.
   PubMed Web of Science ®Google Scholar
• Szamosi T, Mihai K, Peto J, Makary A, Kramer J. Potential markers of the atherosclerotic process in high-risk children. Clin Biochem 1991; 24: 185–7.
   Google Scholar
• Blann AD, Maxwell SR, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endo-thelial cell injury in hypercholesterolemia and vascular disease. Atherosclerosis 1995; 116: 191–8.
   PubMed Web of Science ®Google Scholar
• Guidi G, Schiavon R, Sheiban I, Perona G. Platelet glutathione peroxidase activity is impaired in patients with coronary heart disease. Scand J Clin Invest 1986; 46: 549–51.
   PubMed Web of Science ®Google Scholar
• Buczyfiski A, Wachowicz B, Kgdziora-Kornatowska K, Tkaczewski W, Kqdziora J. Changes in antioxidant enzymes activities, aggregability and malonyldialdehyde concentra-tion in blood platelets from patients with coronary heart disease. Atherosclerosis 1993; 100: 223–8.
   Google Scholar
• Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR. Serum glutathione in adolescent males predicts parental coronary disease. Circulation 1999; 100: 2244–7.
   PubMed Web of Science ®Google Scholar
• Takeshita S, Inoue N, Ueyama T, Kawashima S, Yokoyama M. Shear stress enhances glutathione peroxidase expression in endothelial cells. Biochem Biophys Res Commun 2000; 273: 66–71.
   Google Scholar
• Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep 2000; 2: 98 — 105.
   Google Scholar
• Meilhac 0, Zhou M, Santanam N, Parthasarathy S. Lipid peroxides induce expression of catalase in cultured vascular cells. J Lipid Res 2000; 41: 1205 — 13.
   Google Scholar
• Santanam N, Aug N, Zhou M, Keshava C, Parthasarathy S. Overexpression of human catalase gene decreases oxidased lipid-induced cytotoxicity in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1912–7.
   Google Scholar
• Lapenna D, de Gioia S, Ciofani G, Mezzetti A, Ucchino S, Calafiore AM, Napolitano AM, Di Ilio C, Cuccurullo F. Glutathione-related antioxid-ant defenses in human atherosclerotic plaques. Circulation 1998; 97: 1930–4.
   PubMed Web of Science ®Google Scholar
• Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and patho-physiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175–83.
   Google Scholar
• Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18: 655–73.
   Google Scholar
• Kesavulu MM, Rao BK, Gin i R, Vijaya J, Subramanyam G, Apparao C. Lipid peroxidation and antioxidant enzyme status in type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract 2001; 53: 33–9.
   PubMed Web of Science ®Google Scholar
• Beltowski J, W6jcicka G, Górny D, Marciniak A. The effect of dietary-induced obesity on lipid peroxidation, antioxidant enzymes and total plasma antioxidant capacity. J Physiol Pharmacol 2000; 51: 883–96.
   PubMed Web of Science ®Google Scholar
• Inal ME, Kanbak G, Sunal E. Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin Chim Acta 2001; 305: 75–80.
   Google Scholar
• Guemouri L, Artur Y, Herberth B, Jeandel C, Cuny G, Siest G. Biological variability of super-oxide dismutase, glutathione peroxidase, and catalase in blood. Clin Chem 1991; 37: 1932–7.
   PubMed Web of Science ®Google Scholar
• Bolzan AD, Bianchi MS, Bianchi NO. Superoxide dismutase, catalase and glutathione peroxidase activities in human blood: influence of sex, age and cigarette smoking. Clin Biochem 1997; 30: 449— 54.
   Google Scholar